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A B S T R A C T
There is an urgent need to develop vaginal microbicides to empower women to better control their own
sexual life and to protect themselves against HIV and other sexually transmitted infections (STIs).
Prevention of STIs with its 330 million cases a year would have a great global health impact. Because of
their anatomy, women are up to 8 times more susceptible than men to STIs including HIV. Women who
can’t negotiate condom use with their male partners have no means of protecting themselves from these
infections. In the last few years, especially after the recent failures of several microbicides in Phase III
trials, there was increasing pressure from those favoring the use of a more targeted approach to introduce
marketed antiretroviral drugs (ARVs) into microbicides. This Pre-Exposure Prophylaxis (PrEP) concept
which targets only HIV using speciﬁc ARVs contrasts with the primary approach of broad spectrum
microbicides which aimed at offering universal protection against several sexually transmitted
pathogens. However, before using ARVs as PrEP for HIV prevention, there are still many important issues
to consider. In this article, we compare both strategies, while reviewing the last 15 years of microbicide
research and its future.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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There is an urgent need to develop vaginal microbicides to
empower women to better control their own sexual life and to
protect themselves against HIV and other sexually transmitted
infections (STIs). Researchers have been working hard for more
than 15 years to develop safe and effective microbicides (women-
initiated HIV/STI prevention tools). While it ﬂourished with the
creation of the ‘‘Alliance for Microbicide Development’’ in the USA
12 years ago, the microbicide world changed with the closure of
this unique organization in December 2009 (http://www.micro-
bicide.org/ – page accessed 14 July 2010). The Alliance grouped and
linked major stakeholders, such as researchers, clinicians, advo-
cates, funders, small companies, and organizations (e.g., universi-
ties and research centers) interested in the ﬁeld. It also consulted
with and lobbied implicated government agencies, such as the US
Food and Drug Administration (FDA), for deﬁning the regulatory
path of such a new category of medical products; the US National
Institutes of Health (NIH) and USAID for funding microbicide
research; US Congress and Senate for passing the microbicide
research act offering tax credits, etc. Under the leadership of Dr
Polly Harrison, the Alliance had a major role in deﬁning,
facilitating, and advancing the ﬁeld of microbicides. The Alliance* Corresponding author. Tel.: +1 418 654 2705; fax: +1 418 654 2715.
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ment strategy’’ (2006), ‘‘Mapping the microbicide effort’’ (2007)
and ‘‘Clinical trials site capacity catalogue’’ (2008), and provided
regular ‘‘Microbicide pipeline’’ updates.
In the last few years, especially following the recent failures of
several microbicides to protect against HIV in phase III effective-
ness trials, there has been increasing pressure from those favoring
the use of a more targeted approach, to introduce marketed
antiretroviral drugs (ARVs) that are already being used for HIV
treatment, into gels or creams or even as oral tablets for HIV
prevention. This ‘pre-exposure prophylaxis’ (PrEP) concept, which
targets only HIV using ARVs, contrasts with the primary concept of
broad-spectrum microbicides aimed at offering universal protec-
tion against several sexually transmitted pathogens (Table 1).
There are 330 million cases of curable STIs (syphilis, gonorrhea,
chlamydia and trichomoniasis)1 and 536 million cases of genital
herpes simplex virus (HSV) infection (315 million infected women
compared to 221 million infected men) reported annually
worldwide.2 These numbers are substantially higher than the 33
million people living with HIV reported in 2010 worldwide. Even
though HIV is a more serious infection, the other STIs should not be
neglected. Unlike antiretroviral PrEP, which protects only against
HIV, microbicides would protect against HIV and other STIs as well.
The vagina is an ecosystem where the normal vaginal ﬂora likely
plays a major role in the protection against STIs.3,4 Moreover,
pathogens synergize together to favor their mutual invasion and
dissemination. This is why we need universal non-speciﬁcses. Published by Elsevier Ltd. All rights reserved.
Table 1
Differences between broad-spectrum microbicides and antiretroviral-based pre-exposure prophylaxis
Arguments for broad-spectrum non-speciﬁc microbicides Limitations of anti-retroviral-based pre-exposure prophylaxis
Broad-spectrum microbicides would protect against HIV and other STIs Would protect only against HIV
Some formulations are microbicides and contraceptives as well Would not protect women against unintended pregnancies
Would be available over the counter Would be available by prescription
No risk of resistance with broad-spectrum (non-speciﬁc) microbicides Risk of developing resistance and promoting the selective
transmission of resistant virus
Does not require continuous monitoring of HIV status for implementation Requires continuous monitoring of HIV status for implementation
Universal access could be easier (cheaper) Universal access is questionable (high cost)
Sexually transmitted infections enhance HIV infection (better to prevent both) STIs will not be prevented by PrEP
HIV, human immunodeﬁciency virus; STI, sexually transmitted infection; PrEP, pre-exposure prophylaxis.
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Anthony Fauci, Director of the National Institute of Allergy and
Infectious Diseases (NIAID) at the NIH was quoted to say
‘‘Microbicides without ARVs aren’t a dead issue, but they are
deﬁnitely on a resuscitator’’ (International AIDS Vaccine Initiative
(IAVI) Report, January–February 2010 issue)
2. Women and microbicides
The microbicide ﬁeld was created because women are up to
eight times more susceptible than men to STIs, including HIV, due
to their anatomy.5 They have large exposed surfaces of vaginal and
cervical mucosae that need to be protected against sexually
transmitted pathogens. Women who cannot negotiate condom use
with their male partners have no means of protecting themselves
from HIV and other STIs. As well as being female-controlled
discrete products, microbicides offer broad-spectrum activity
against many sexually transmitted pathogens, such as HIV, HSV,
human papillomavirus (HPV), Neisseria gonorrhoeae, Chlamydia
trachomatis, etc. compared to PrEP, which offers targeted protec-
tion against only HIV. Microbicides were deﬁned in 1998 as
follows: ‘‘A microbicide is a substance that can substantially
reduce the sexual transmission of STIs when applied into the
vagina or rectum’’ (http://www.microbicide.org/). A microbicide
can either be a microbicide alone or both a microbicide and a
contraceptive at the same time, offering dual protection against
HIV/other STIs and unintended pregnancy. One of the most
important aspects of microbicides, once available, would be that
they could be over-the-counter products controlled 100% by
women. If we transform microbicides into PrEP, they will most
likely be prescription ‘drugs’, which risks a substantial reduction in
their impact on public health.
Apart from the female condom, which is expensive and
cumbersome to use (compared to the male condom), there are
no other means of protection under the control of women. Women
urgently need such a universal life-saving protection tool
(microbicides), like men, who have had the option of male
condoms as universal protection for many years. The impact of
latex male condoms on STIs has been demonstrated for more than
170 years, since they became available after Charles Goodyear
introduced rubber in 1839 (http://www.cdc.gov/nchstp/od/con-
doms.pdf (accessed September 21, 2010); http://en.wikipedia.org/
wiki/Condom (accessed July 14, 2010)). Furthermore, HIV and STIs
cannot be separated. It is now well-recognized that STIs increase
the risk of contracting HIV.6,7 Male condoms, when used
consistently and correctly, represent an efﬁcient barrier against
HIV/STIs, but, unfortunately they are only used in about one-third
of risky sexual intercourse where there is a need to be protected.8,9
On the other hand, women have shown a positive attitude towards
vaginal microbicides, and studies have shown that women would
be willing to use vaginal microbicides, once available, to protect
themselves.10–13 Professor Salim S. Abdool Karim, Director of the
Centre for the AIDS Programme of Research in South Africa(CAPRISA), said: ‘‘Despite numerous scientiﬁc, ethical and meth-
odological challenges, microbicides provide real potential to
inﬂuence the course of the HIV epidemic as they could ﬁll an
important gap for women-initiated prevention methods’’.14
3. The ideal vaginal microbicide
An ideal vaginal microbicide should have all or most of the
following important and desirable characteristics. As well as the
two pillars of new drug development – being safe and effective –
the ideal microbicide topical formulation should: (1) have similar
acidic pH to that of the normal vagina, (2) not affect the normal
vaginal ﬂora, (3) remain in the vagina for a few hours (ideally
between 4 and 8 h, enough time to react against STIs during and
after sexual intercourse), (4) not accumulate (to avoid toxicity to
the protective genital mucosa), (5) be acceptable and affordable,
(6) not leak immediately after application and not soil underwear,
and (7) be compatible with male latex condoms.15 In addition, to
offer maximal and immediate protection, it should have complete
and homogeneous vaginal and cervical mucosal coverage with a
unique applicator design.
A female-controlled prevention tool could result in averting
millions of infections and could save millions of lives worldwide.16
In addition, vaginal microbicides could be cost-effective and could
save money in countries where HIV prevalence exceeds 2.4% and in
countries where there is a generalized epidemic, such as South
Africa.17 Since the 1950s, we have lived in a therapeutic world of
the treatment of infections with drugs (Bug–Drug war). We should
change our way of thinking and favor prevention of infections. This
will result in fewer infections to treat and will certainly reduce the
cost of public health care.
4. Why did previous microbicides fail?
It is inherently difﬁcult to conduct HIV prevention microbicide
effectiveness trials. There are many scientiﬁc, ethical, and
methodological challenges.18–21 The reasons for the failures of
previously investigated microbicide products in phase III trials are
not fully known or understood, and the following discussion is not
intended to be comprehensive. Effectiveness results depend on
several factors; some of them are difﬁcult to control or to estimate
precisely. Such factors include: product efﬁcacy in the complex real
vaginal environment, product use before each sexual intercourse
(adherence), time off product due to pregnancy, homogeneous
coverage of the vaginal and cervical mucosal surface by the topical
microbicide formulation, and the real HIV incidence rate in the
target tested sub-population. We have a lot of respect for those
courageous researchers who have gone through difﬁcult phase III
microbicide effectiveness trials in resource-limited settings, such
as the sub-Saharan Africa region, with the goal of offering women,
some day, a safe and effective microbicide. We have conducted a
phase II safety trial in Cameroon and we know the challenges.22,23
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phase III microbicide effectiveness trials in which tested products
failed to protect against HIV. It all started with the spermicide
nonoxynol-9,24,25 followed by SAVVY (C31G),26,27 cellulose sul-
fate,28 Carraguard,29 BufferGel,30 and ﬁnally PRO 2000.31 Nonoxy-
nol-9 and SAVVY are surfactants; cellulose sulfate, PRO 2000, and
Carraguard are entry inhibitors; BufferGel is an acid buffer gel. The
failures of nonoxynol-9 and cellulose sulfate to protect women
against HIV in phase III microbicide effectiveness trials were most
likely because they caused, upon repeated vaginal use, disruption
of the protective genital epithelial barrier and enhanced viral
replication.25,32 SAVVY (C31G) was not effective in protecting
women from Ghana against HIV and was associated with a higher
incidence of reproductive adverse events.26 In the Nigeria trial,
there was a total of 33 seroconversions: 21 in the SAVVY group and
12 in the placebo group.27 In that trial, the HIV incidence rate was
lower than anticipated. For PRO 2000, seminal plasma was shown
to reduce its effectiveness as a microbicide.33 In addition, PRO 2000
was shown to reduce protective mucosal immune mediators, such
as interleukin-1 receptor antagonist and beta-defensin 2.34
Despite the recent disappointing outcomes, those trials
provided a better understanding of the factors that may reduce
the effectiveness of potential products in development. In addition
to the above-listed possible reasons, and apart from adherence
problems (not using the product before each vaginal intercourse)
in some phase III trials, those topical microbicide products that
failed to protect women against HIV were intravaginally delivered
using conventional applicators with only one apical hole to deliver
the product to the cervix region and posterior fornix, leaving the
large surface of the vaginal mucosa exposed to infection. Such a
conventional applicator design also allows the topical microbicide
product to remain in the upper vagina and cervix region for more
than 24 h, risking product accumulation and the introduction of
cervical/vaginal toxicity/inﬂammation/effects on mediators of
host defense, which may result in an increased risk of acquiring
HIV, either by increasing the susceptibility to infection or by
decreasing the innate protective immune response; this does not
apply to ARV-based PrEP. We believe that the type of applicator
may play a crucial role in increasing efﬁcacy and preventing
toxicity of topical microbicides. This is why we have designed, for
our microbicide, the Invisible Condom1, a unique vaginal
applicator with multiple apical and lateral holes, which has been
demonstrated (using magnetic resonance imaging) to offer
immediate uniform distribution of the microbicide formulation
to cover the vagina, cervix, and posterior fornix.35 Moreover,
besides covering, within a few minutes compared to the
conventional applicator, all the potential ports of entry of HIV
and other STIs, our applicator allowed the gel formulation to
remain within the vaginal vault for between 4 and 8 h following
active sex (enough time to offer protection during and after sexual
intercourse without the risk of accumulation for 24 h).35 Finally,
the formulation of a microbicide product is important for reducing
the potential toxicity of universal anti-infective active compounds
and for making them available at the right dose for efﬁcacy without
causing toxicity (slow-release delivery). Interestingly, none of the
products that failed in phase III clinical trials had a similar slow-
release system. In that regard, we demonstrated more than a
decade ago that our vaginal gel formulation protected against the
marked toxic effects of the known spermicide nonoxynol-9.36
5. Nonoxynol-9
Based on our analyses of the microbicide candidates that failed
phase III effectiveness trials, we strongly believe that among the
major reasons for their failures are their mucosal toxicity, the way
they were applied into the vagina, poor adherence to product use,and over-estimated HIV incidence in high-risk populations at the
clinical sites. Used as a contraceptive since the 1960s at a time
when the FDA and other regulatory agencies did not have rules as
stringent as they are today, and based on in vitro microbicide
efﬁcacy data, it was logical to evaluate nonoxynol-9 as a possible
microbicide. Based on our previous studies where we demonstrat-
ed that nonoxynol-9 was markedly toxic to the vaginal and cervical
mucosae,36 it was no surprise that it failed as a microbicide
candidate. The intense genital mucosal toxicity and ulcerations
caused by the repeated vaginal use of nonoxynol-9 was plainly
evident.24,25,36–39 Consequently, many researchers stayed away
from all surfactants, forgetting that there are hundreds of
surfactants with different therapeutic indices (the ratio between
the toxic dose and the effective dose), which can be controlled by
an appropriate drug delivery system to release the appropriate safe
and effective dose.
6. The prejudice against surfactants
Consequent to the failures of nonoxynol-9, SAVVY (C31G),
cellulose sulfate, and PRO 2000 as microbicides, the attack on
surfactants and non-speciﬁc anti-HIV compounds increased
substantially. Many researchers indiscriminately placed all non-
speciﬁc anti-HIV compounds in the same basket, without a
scientiﬁc basis to back up their fear.14,40,41 A group of researchers
even harshly criticized the earlier microbicide efforts in an article
entitled ‘‘Whither or wither microbicides?’’.41 This resulted in a
reply, in the same journal Science, from a larger international group
of researchers well known in the ﬁeld, to defend the microbicide
cause: ‘‘What we cannot do is wait. The need for effective HIV
prevention methods is too great’’.18
Before judging surfactants, one has to understand more about
them ﬁrst. Surfactants are wetting agents that lower the surface
tension of a liquid, allowing easier spreading. Surfactant molecules
in solution at certain concentrations tend to self-assemble to form
aggregates called micelles. The concentration at which surfactants
begin to form micelles is known as the critical micelle concentra-
tion (CMC).
There are many types of surfactant. There are denaturing
surfactants that are either anionic (negatively charged, e.g., sodium
lauryl sulfate (SLS)) or cationic (positively charged, e.g., benzalk-
onium chloride), and non-denaturing surfactants that are either
zwitterionic (exhibiting both anionic and cationic dissociations,
e.g., dodecyl-N-betaine) or non-ionic (do not ionize in aqueous
solution, e.g., nonoxynol-9). In terms of their relative toxicity, these
rate as follows: cationic > zwitterionic = nonionic > anionic. As we
can see, SLS falls under the least toxic category of surfactant
(anionic surfactant). Furthermore, nonoxynol-9 indiscriminately
solubilizes lipid membranes below the CMC (0.004%), whereas SLS
interacts with, unfolds, denatures, and extracts protein below the
CMC (0.066%) and solubilizes membrane lipids at concentrations
close to the CMC. The Invisible Condom microbicide/contraceptive
gel formulation with SLS contains 2% SLS, which is 30 its CMC. Its
microbicide effective concentrations in vitro are 0.00144–
0.01442%, which are 140–1400 less than its concentration in
formulation and 4.6–46 less than its CMC (data on ﬁle at the US
FDA, IND number 62894). Being formulated in the polymer gel, SLS
is slowly released and gradually becomes available at the right
effective, but not toxic concentration (favorable therapeutic index)
(data on ﬁle at the US FDA, IND number 62894). SLS effectiveness
and lack of toxicity have been demonstrated in the laboratory and
in phase I and phase II safety clinical trials in North America and in
sub-Saharan Africa.15,22,23,35,36,42–51 SLS was also shown (by the
late Dr Mary K. Howett and her group in Pennsylvania) to be
substantially less toxic than nonoxynol-9, by as much as 30–100
times less toxic, depending on the assay used.52 Finally, SLS is
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children use safely on a daily basis, such as shampoos, toothpaste,
dental rinse, nasal decongestants, and even in vaginal cream
formulation (Premarin1).
7. The risks of using ARVs as PrEP
Immediately following the release of negative results of each of
the ﬁve effectiveness microbicide trials mentioned above, many
researchers wrote about those trials and the ‘lessons learned’ from
them.14,18,40,53 However, surprisingly, hardly anyone talked about
the types of applicator used for delivery or the slow delivery
system of microbicides. Because of these unsuccessful products
and their lack of protection against HIV, the ﬁeld of broad-
spectrum topical microbicide development suffered a backlash,
thus explaining the recent rush for an HIV-targeted approach using
ARVs as PrEP. Pre-exposure prophylaxis aims at using approved
antiretroviral drugs (nucleoside and non-nucleoside reverse
transcriptase inhibitors) that are already being used to treat
patients with HIV/AIDS for HIV prevention. Several research
groups turned their backs on universal microbicides and changed
their position to support the use of ARVs as PrEP.41,54–58
As microbicide researchers, we were very pleased with the
recent press release at the XVIII International AIDS Conference in
Vienna, Austria on July 20, 2010 of the CAPRISA 004 trial results
showing 39% protection against HIV when using topical tenofovir
(antiretroviral drug) vaginal gel; this certainly gave higher hopes in
the use of ARVs as PrEP.59We, as microbicide researchers, share the
enthusiasm of the South African researchers who led the study and
have renewed our commitment to continue the research to provide
women with a safe and effective microbicide. However, there are
still many important issues to consider before using ARVs as PrEP
for HIV prevention.
The risk of developing resistance to ARVs when widely used as
PrEP is a major concern. This could leave HIV/AIDS patients
needing treatment devastated. At the recent International Micro-
bicides Conference 2010 in Pittsburgh, PA, USA (May 2010), Dr John
Mellors of the University of Pittsburgh expressed concern at the
‘‘substantial overlap in the drugs being used for treatment and
those being studied for prevention’’. He said that in a worst-case
scenario, widespread resistance at a population level to these drugs
could end up rendering them ineffective for both treatment and
prevention.60 Because of the probability of yielding relatively high
levels of antiretroviral resistance, it is recommended that careful
and regular population-level monitoring occur to monitor for
resistance if, and when, antiretroviral-based microbicides are used
widely in public health interventions.61 Resistance could increase
if people who are unknowingly infected with HIV use PrEP.56
Therefore, it is recommended that HIV testing and ongoing
monitoring of infection status be incorporated into prevention
programs using ARVs. The cost implicated to implement this
strategy worldwide and in resource-limited and poor countries
such as those of the sub-Saharan Africa region would be
tremendous.
The big question remains: How are we going to ensure universal
access to expensive antiretroviral-containing PrEP? So far, we are
not doing well in terms of universal access to ARVs for the
treatment of HIV-infected patients: ‘‘for every 100 people put on
antiretroviral treatment, 250 people are getting newly infected
with HIV’’, UNAIDS 2010. It was even worse a few years before,
especially for people in low- and middle-income countries: ‘‘Less
than one in ten people who need antiretroviral therapy receive it’’,
UNAIDS 2004.62 In addition, being prescription drugs, access to
ARVs will continue to be a major problem. In our opinion,
new preventive tools should be affordable and available over-
the-counter, as are male condoms, for universal access andimplementation. Furthermore, we need to treat between 100
and 10 000 uninfected people to prevent one HIV transmission,
because the chance of HIV sexual transmission from an infected
sexual partner is 1:100 to 1:10 000 depending on the infection/
disease stage and viral load of the infected person.63,64
Vaginal microbicides and ARV-PrEP share some issues, such as
adherence problems, the risk of changing sexual risk behavior, and
whether they would suppress the transmission of HIV under ‘real
life’ conditions.65
8. Conclusions
The verdict is not yet out on whether broad-spectrum
microbicides and/or HIV targeted microbicides will be the most
effective agents. We are not against ARV-based PrEP, but we have
to be cautious and all opinions have to be heard. What we have
observed in the last year with the closure of the Alliance for
Microbicide Development and the attitude of the research
community towards broad-spectrum microbicides, which have
not been fully explored, is sad. We need to continue to explore all
the avenues that could result in safe and efﬁcient products that
would be acceptable to women. We hope that one day there will be
several low-cost over-the-counter microbicides that will give
women the opportunity to control their own sexual life and protect
themselves against HIV and other STIs, plus or minus unwanted
pregnancy. ‘‘No prevention stone should go unturned’’.65
With the ultimate goal of eradicating HIV/other STIs and
empowering women to protect themselves against these infec-
tions, the way forward for all implicated stakeholders, including
researchers in this ﬁeld, should be to collaborate in order to
introduce integrated and complementary strategies that will
control HIV and other STIs: (1) prior to exposure: education and
behavior change, male circumcision, preventive vaccines, micro-
bicides, rapid diagnostics; (2) at the point of transmission: male
and female condoms, antiretroviral therapy (mother-to-child),
post-exposure prophylaxis; (3) after infection: antiretroviral
therapy, care, education and behavioral change, therapeutic
vaccines. We believe that there is a need to continue to pursue,
with caution, the research on both the universal microbicides with
efﬁcacy against a wide range of STIs, including HIV, and the
targeted microbicides (PrEP) with targeted efﬁcacy against only
HIV. Furthermore, microbicides, once proven safe and effective,
should be acceptable, low-cost, and accessible (over-the-counter
not by prescription). ‘‘What we can’t do is wait. The need for
effective HIV/STIs prevention methods is too great’’.18
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